脂质体与肾透明细胞癌的遗传关系:一项两样本孟德尔随机化研究
Genetic Relationship between Lipidomes and Clear Cell Renal Cell Carcinoma: Two-Sample Mendelian Randomization Study
摘要: 目的:现有研究表明,脂质体水平与肾透明细胞癌(Clear Cell Renal Cell Carcinoma, ccRCC)之间存在相关性。然而,对于脂质体与肾透明细胞癌之间的因果关系,现有文献尚未达成一致意见。本研究采用两样本孟德尔随机化(Mendelian Randomization, MR)分析来严格评估两者之间的因果关系。方法:采用可公开获取的全基因组关联研究(GWSA)数据库进行MR分析。本研究的中心方法是逆方差加权(Inverse-Variance Weighting, IVW)荟萃分析,同时联合贝叶斯加权孟德尔随机化(Bayesian Weighted Mendelian Randomization, BWMR)进一步验证结果,Cochran’s Q和MR-Egger等方法进行补充研究。结果:在MR结合BWMR分析中,发现8个与ccRCC具有直接因果关联的脂质体。卵磷脂O-18:2_16:0 (OR: 0.766, 95%CI: 0.605~0.970, p = 0.027)降低ccRCC发病风险;卵磷脂16:0_0:0 (OR: 1.231, 95%CI: 1.002~1.514, p = 0.048)、卵磷脂18:1_18:3 (OR: 1.609, 95%CI: 1.117~2.318, p = 0.011)、卵磷脂O-16:0_20:4 (OR: 1.188, 95%CI: 1.013~1.393, p = 0.034)、脑磷脂16:0_20:4 (OR: 1.173, 95%CI: 1.020~1.348, p = 0.025)、脑磷脂18:0_20:4 (OR: 1.359, 95%CI: 1.149~1.608, p = 0.001)、甘油三酯48:1 (OR: 1.259, 95%CI: 1.002~1.523, p = 0.048)及甘油三酯48:2 (OR: 1.292, 95%CI: 1.033~1.615, p = 0.025)增加ccRCC患病风险。结论:基因预测结果显示脂质体与肾透明细胞癌之间存在遗传因果关系,这为未来更多的临床研究提供了理论支持和基础。
Abstract: Objective: Existing studies suggest an association between lipidomes levels and clear cell renal cell carcinoma (ccRCC). However,consensus regarding the causal relationship between lipidomes and ccRCC has not been reached in current literature. This study aimed to rigorously assess the causal relationship between lipidome levels and ccRCC using Mendelian randomization (MR) analysis with two independent samples. Methods: Mendelian randomization analysis was conducted using publicly available genome-wide association study (GWSA) databases. The central method employed was inverse-variance weighting(IVW)meta-analysis, supplemented by Bayesian weighted Mendelian randomization(BWMR)to further validate the results, along with methods such as Cochran’s Q and MR-Egger. Results: In the MR combined with BWMR analysis, eight lipidomes traits were found to have a direct causal association with ccRCC. Decreased levels of phosphatidylcholine O-18:2_16:0 (OR: 0.766, 95%CI: 0.605~0.970, p = 0.027) were associated with a reduced risk of ccRCC. Increased risk of ccRCC was associated with phosphatidylcholine 16:0_0:0 (OR: 1.231, 95%CI: 1.002~1.514, p = 0.048), phosphatidylcholine 18:1_18:3 (OR: 1.609, 95%CI: 1.117~2.318, p = 0.011), phosphatidylcholine O-16:0_20:4 (OR: 1.188, 95%CI: 1.013~1.393, p = 0.034), phosphatidylethanolamine 16:0_20:4 (OR: 1.173, 95%CI: 1.020~1.348, p = 0.025), phosphatidylethanolamine 18:0_20:4 (OR:1.359, 95%CI:1.149~1.608, p = 0.001), triglyceride 48:1 (OR: 1.259, 95%CI: 1.002~1.523, p = 0.048), and triglyceride 48:2 (OR: 1.292, 95%CI: 1.033~1.615, p = 0.025). Conclusion: Genetic prediction indicates a causal relationship between lipidome levels and ccRCC, providing theoretical support and a basis for future clinical research.
文章引用:王伟昊, 赵科元, 潘寿华. 脂质体与肾透明细胞癌的遗传关系:一项两样本孟德尔随机化研究[J]. 临床医学进展, 2024, 14(6): 1182-1189. https://doi.org/10.12677/acm.2024.1461896

参考文献

[1] Hsieh, J.J., Purdue, M.P., Signoretti, S., Swanton, C., Albiges, L., Schmidinger, M., et al. (2017) Renal Cell Carcinoma. Nature Reviews Disease Primers, 3, Article No. 17009. [Google Scholar] [CrossRef] [PubMed]
[2] Bukavina, L., Bensalah, K., Bray, F., Carlo, M., Challacombe, B., Karam, J.A., et al. (2022) Epidemiology of Renal Cell Carcinoma: 2022 Update. European Urology, 82, 529-542. [Google Scholar] [CrossRef] [PubMed]
[3] Stolpa, W., Stręk-Cholewińska, A. and Mizia-Malarz, A. (2022) Clear Cell Renal Cell Carcinoma, Diagnostic and Therapeutic Difficulties, Case Report and Literature Review. Medicina, 58, Article 1329. [Google Scholar] [CrossRef] [PubMed]
[4] Hampel, H., Nisticò, R., Seyfried, N.T., Levey, A.I., Modeste, E., Lemercier, P., et al. (2021) Omics Sciences for Systems Biology in Alzheimer’s Disease: State-of-the-Art of the Evidence. Ageing Research Reviews, 69, Article 101346. [Google Scholar] [CrossRef] [PubMed]
[5] Yoon, J.H., Seo, Y., Jo, Y.S., Lee, S., Cho, E., Cazenave-Gassiot, A., et al. (2022) Brain Lipidomics: From Functional Landscape to Clinical Significance. Science Advances, 8, eadc9317. [Google Scholar] [CrossRef] [PubMed]
[6] Zou, Y., Henry, W.S., Ricq, E.L., Graham, E.T., Phadnis, V.V., Maretich, P., et al. (2020) Plasticity of Ether Lipids Promotes Ferroptosis Susceptibility and Evasion. Nature, 585, 603-608. [Google Scholar] [CrossRef] [PubMed]
[7] Skrivankova, V.W., Richmond, R.C., Woolf, B.A.R., Yarmolinsky, J., Davies, N.M., Swanson, S.A., et al. (2021) Strengthening the Reporting of Observational Studies in Epidemiology Using Mendelian Randomization: The STROBE-MR Statement. JAMA, 326, 1614-1621. [Google Scholar] [CrossRef] [PubMed]
[8] Dudbridge, F. (2020) Polygenic Mendelian Randomization. Cold Spring Harbor Perspectives in Medicine, 11, a039586. [Google Scholar] [CrossRef] [PubMed]
[9] Antoni, S., Ferlay, J., Soerjomataram, I., Znaor, A., Jemal, A. and Bray, F. (2017) Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends. European Urology, 71, 96-108. [Google Scholar] [CrossRef] [PubMed]
[10] Pigeyre, M., Sjaarda, J., Chong, M., Hess, S., Bosch, J., Yusuf, S., et al. (2020) ACE and Type 2 Diabetes Risk: A Mendelian Randomization Study. Diabetes Care, 43, 835-842. [Google Scholar] [CrossRef] [PubMed]
[11] Burgess, S., Butterworth, A. and Thompson, S.G. (2013) Mendelian Randomization Analysis with Multiple Genetic Variants Using Summarized Data. Genetic Epidemiology, 37, 658-665. [Google Scholar] [CrossRef] [PubMed]
[12] Zhao, J., Ming, J., Hu, X., Chen, G., Liu, J. and Yang, C. (2019) Bayesian Weighted Mendelian Randomization for Causal Inference Based on Summary Statistics. Bioinformatics, 36, 1501-1508. [Google Scholar] [CrossRef] [PubMed]
[13] Burgess, S. and Thompson, S.G. (2017) Interpreting Findings from Mendelian Randomization Using the MR-Egger Method. European Journal of Epidemiology, 32, 377-389. [Google Scholar] [CrossRef] [PubMed]
[14] Burgess, S. and Thompson, S.G. (2015) Multivariable Mendelian Randomization: The Use of Pleiotropic Genetic Variants to Estimate Causal Effects. American Journal of Epidemiology, 181, 251-260. [Google Scholar] [CrossRef] [PubMed]
[15] Du, Y., Wang, Q., Zhang, X., Wang, X., Qin, C., Sheng, Z., et al. (2017) Lysophosphatidylcholine Acyltransferase 1 Upregulation and Concomitant Phospholipid Alterations in Clear Cell Renal Cell Carcinoma. Journal of Experimental & Clinical Cancer Research, 36, Article No. 66. [Google Scholar] [CrossRef] [PubMed]
[16] Hannun, Y.A. and Obeid, L.M. (2017) Sphingolipids and Their Metabolism in Physiology and Disease. Nature Reviews Molecular Cell Biology, 19, 175-191. [Google Scholar] [CrossRef] [PubMed]
[17] Rao, H., Liu, C., Wang, A., Ma, C., Xu, Y., Ye, T., et al. (2023) SETD2 Deficiency Accelerates Sphingomyelin Accumulation and Promotes the Development of Renal Cancer. Nature Communications, 14, Article No. 7572. [Google Scholar] [CrossRef] [PubMed]
[18] Yue, D. and Tian, J. (2023) Serum Uric Acid and Triglycerides in Clear Cell Renal Cell Carcinoma: A Restrospective Cross-Sectional Study. Medicine, 102, e34645. [Google Scholar] [CrossRef] [PubMed]
[19] Klymkowsky, M.W. and Savagner, P. (2009) Epithelial-Mesenchymal Transition: A Cancer Researcher’s Conceptual Friend and Foe. The American Journal of Pathology, 174, 1588-1593. [Google Scholar] [CrossRef] [PubMed]
[20] Li, W., Wang, X., Zhang, X., Gong, P., Ding, D., Wang, N., et al. (2021) Revealing Potential Lipid Biomarkers in Clear Cell Renal Cell Carcinoma Using Targeted Quantitative Lipidomics. Lipids in Health and Disease, 20, Article No. 160. [Google Scholar] [CrossRef] [PubMed]